We reported the results of a comparative analysis in terms of pCR, EFS, and safety on the addition of pertuzumab to trastuzumab and taxane-based regimens as neoadjuvant chemotherapy for HER-2-positive early breast cancer. The gene discussed is ERBB2; the disease is breast cancer.